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Introduction
Nodular lymphocyte-predominant Hodgkin lymphoma
(NLPHL) is an indolent Hodgkin lymphoma (HL) entity
counting for 5% of all HLs [1]. However, it seems to
be a biologically distinct disease with a favorable prog-
nosis with an 80% 10-year overall survival without any
lymphoma treatment [2]. Unlike in classical Hodgkin
lymphoma (cHL), neoplastic cells are positive for CD20.
Due to the indolent nature of the disease, deaths
caused by NLPHL without further histological progression
are uncommon [3]. The clinical course of the disease is
indolent, but multiple relapses occur occasionally [4].
Unlike in cHL, a transformation to other lymphomas
such as T-cell rich B-cell lymphoma or diffuse large B-
cell lymphoma may occur [4,5].
Most patients are treated with a regimen developed
for cHL. Treatment with cHL protocols leads to complete
response (CR) in >95% of cases [6]. However, it has
been suggested that NLPHL would not require as
aggressive treatment as cHL. Therefore, chemotherapy
followed by radiation therapy (RT) may not be the best
option for NLPHL [7]. The majority of NLPHL patients
die of cardiac disease or secondary malignancy, which
are often consequences of previous lymphoma treat-
ments [3]. For these reasons, there is an unmet clinical
need to find an effective treatment regimen with less
long-term toxicity.
The CD20 antibody rituximab is often used in
advanced-stage, recurrent and refractory NLPHL [8].
Rituximab has been shown to induce good response rates
(RRs) in first-line treatment and in relapsed and refractory
cases [9,10].
In the last 5 years in Oulu University Hospital, NLPHL
patients have been treated with R-bendamustine to minimize
therapy-associated toxicity. In the present work, we retrospect-
ively collected and analyzed the data to evaluate the feasibility
of this strategy.
Material and methods
This is a retrospective registry study. We collected clinical
data from hospital records of NLPHL patients who were
treated with R-Bendamustine either in first line or after the
first relapse. Data was collected from Oulu University Hospital
in Finland.
Patients were diagnosed between 2001 and 2016. The
diagnoses were reviewed by experienced hematopatholo-
gists. Information such as age, stage, ECOG performance sta-
tus, details of treatment, possible relapses and the current
status were investigated. Event free survival (EFS) was calcu-
lated from the date of first day of first chemotherapy cycle
up to the date of the disease relapse or the last follow-up
date. Patients lost from follow-up were censored at the last
day of documented survival.
Results
In total, nine patients treated with R-bendamustine were
found. Patient demographics are given in Table 1. The
median age was 46.5 years. Of patients 7/9 were male, 8/9 of
patients presented advanced-stage disease and 1/9 of
patients had B-symptoms. The median follow-up time after
NHL treatment was 34.0 months (14–79).
Treatments
Seven patients were treated frontline and two in the first
relapse. From relapsed patients, one patient was treated with
RT only in frontline and one was treated with AVBD in
frontline.
Treatment outcomes
RR in the whole patient group was found to be 9/9 and CR
was achieved in 9/9 of the patients. After a median follow-up
CONTACT Roosa Prusila roosa.prusila@student.oulu.fi University of Oulu, Oulu, Finland
 2018 Acta Oncologica Foundation
https://doi.org/10.1080/0284186X.2018.1450522
ACTA ONCOLOGICA
2018, VOL. 57, NO. 9, 1265–1274
period of 34 months, the EFS was 9/9. During our follow-up,
none of the patients have relapsed.
Toxicity
One patient had been changed to R-CEOP therapy after two
cycles of R-bendamustine due to an allergic reaction related
to bendamustine.
Discussion
In the present work, we report that with relatively short fol-
low-up time that the treatment outcome of R-bendamustine
is excellent in NLPHL patients.
NLPHL is an indolent disease with an insignificant risk of
death without a histological transformation. There is a series
of 23 patients with NLPHL published with median survival of
16 years without any lymphoma treatment [11].
NLPHL has traditionally been treated like other HL sub-
types. Treating NLPHL with cHL regimens provides good
results in the term of disease control. In advanced-stage
patients treated with ABVD, 5- and 10-year OS of 89 and
83.5% have been reported [12]. With a small number of
patients treated with R-ABVD, the estimated 6-year PFS and
OS of 75 and 100% have been shown [13]. One of the major
concerns for the therapy for HL is long-term toxicity [14].
Actually, the treatment-induced side effects cause higher
mortality than the disease itself [15].
The most common nonmalignant causes of death in
patients treated for HL are the cardiovascular diseases. RT
and chemotherapy are both linked to an increased risk of
cardiac mortality. Patients treated with ABVD have a 7.8
times higher risk of death from myocardial infarction than
the general population and patients who received medias-
tinal RT have 2.6 times higher risk of myocardial infarction
than patients treated without RT [16]. Combined use of
chemotherapy and RT increase the risk of cardiac toxicity
more than either of the treatment methods alone [17].
Another group of important late effects of HL treatment
are secondary malignancies. Both RT and chemotherapy are
associated with higher risk of secondary malignancies,
increasing the risk of leukemia, breast cancer, lung cancer
and gastrointestinal cancer [18]. In NLPHL, secondary malig-
nancies have been found to be the main cause of death dur-
ing a long follow-up on patients treated with RT only [3].
There is not much experience of the use of NHL treat-
ments in NLPHL patients. Fanale et al. [11] have treated 59
advanced-stage patients with R-CHOP showing 5- and 10-
year PFS of 88.5 and 59.3%. The 5-year cumulative incidence
of transformation was shown to be 2%. Another report of 12
patients with advanced-stage disease treated with R-CHOP
has been published with an overall RR of 100% and CR rate
of 90%. No relapses or transformations were detected within
the median follow-up time of 42 months [19]. In contrast to
classical Hodgkin’s lymphoma, NLPHD is a CD20 positive dis-
ease [1,6], which enables the use of CD20 antibody rituximab.
The use of rituximab only and rituximab maintenance with-
out chemotherapy seems to be effective but provides only
short remissions [20].
Bendamustine is a drug that offers a favorable risk-benefit
profile. One important issue is that with bendamustine it’s
possible to avoid anthracycline therapy and the potential risk
of anthracycline cardiomyopathy. With NHL patients, R-bend-
amustine has been used for patients with indolent disease
and in aggressive disease in patients not eligible for R-CHOP
due to cardiac insufficiency [21]. The most common side
effects of bendamustine are myelosuppression and infections
[22]. Myelodysplastic syndromes have been connected to the
use of bendamustine [23] but the incidence of is not well-
known [24].
There are so far no data available of NLPHL patients
treated with R-bendamustine. In this retrospective analysis,
we observed a 100% CR rate and a 100% PFS rate with a
median follow-up of 34 months. The data presented here
indicates that R-bendamustine might serve as a well-toler-
ated and effective option for the treatment of NLPHL.
Approximately 20% of NLPHL patients have advanced-
stage disease [3]. Advanced-stage NLPHL is a more aggres-
sive disease with poorer RRs and OS. In a series of 55
patients, patients with limited-stage disease (I–II) had 5-year
PFS of 76.4% while those with advanced-stage disease (III–IV)
show a 5-year PFS of only 29.9% [25]. According to Swedish
registry data, patients with early-stage disease (I–IIA) had a
10-year OS of 85% and with advanced-stage disease (IIB–IV)
the 10-year OS was 64% [26]. In the present patient group,
8/9 of cases had advanced-stage disease. Despite the fact
that most patients treated with R-bendamustine had an
advanced-stage disease, good treatment responses were
achieved.
Due to the rarity of this disease only a limited number of
patients were eligible for this study. The patient group is also
heterogeneous, and the follow-up time for the patients was
quite short. These results should, thus, be interpreted with
caution.
Conclusions
This is a preliminary study showing that R-bendamustine is
promising candidate for the therapy of NLPHL. However, the
Table 1. Patient demographics.
Characteristic Result Data available (n)
Age (years) Median
46.5 (19–61)
9
Sex 9
Male 7/9
Women 2/9
Stage 9
1 1/9
3 6/9
4 2/9
B-symptoms 1/9 9
LDH 6
Elevated 1/6
ECOG performance status 5
0 5/5
Line of treatment 9
First line 7/9
First relapse 2/9
Previous treatments
ABVD 1
RDT 1
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results of this study should be verified in larger prospective
trials.
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